ClinicalTrials.gg
RecruitingNCT05725200EVIDENTUpdated Feb 21, 2023

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of Alectinib and Cetuximab in Metastatic Colorectal Cancer, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Oslo University Hospital · Phase 2, Interventional, and Treatment

How we know · 36 judgments

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2022, registered Jan 2023).
  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Planned enrollment
117th of 185
40 · median 60
Started
2022
with 2 others
Phase 2
107 of 187
20 open now
Primary completion
2038-12
later than 42 of 42 live
Registered
150th of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 117th largest by planned enrollment of the 185 interventional ones that give a count, is one of 3 that started in 2022, is one of 107 in phase 2, reaches primary completion later than 42 of the 42 other live ones, and was the 150th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Read the detailed description

The purpose of the study is to evaluate individualized systemic anti-cancer treatment of metastatic colorectal cancer (mCRC), selected by a combined pharmacogenomic drug sensitivity profile with a molecular profiling of the tumor tissue and an ex vivo drug sensitivity testing of patient-derived organoids (PDOs). The combined pharmacogenomic drug sensitivity profile will be provided by Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital (OUS) and will be a result of either i) a pre-screening performed in this study or ii) from previous biomarker analyses and drug sensitivity testing of PDOs as part of an ongoing translational research project at Dept. of Molecular Oncology. The combined pharmacogenomic profile will be interpreted by an institutional multidisciplinary tumor board (MTB), and in cases where the MTB strongly suggests that the patient will benefit from one of the interventions offered by this study, the patient will be invited to participate. No formal hypotheses testing will be performed in the study, but it aims to show that it is feasible, in an unselected population of patients with mCRC, to select patients for individualized therapy based on a broad genomic and transcriptomic profiling and ex vivo drug sensitivity testing of cultured PDOs from the patient's own tumor cells, and to provide evidence that a combined pharmacogenomic profile can predict objective antitumor responses to systemic anticancer therapies, including drugs not approved for treatment of patients with mCRC, in the setting of third-line therapy or in later lines. In addition, this study will be part of several translational research projects at the Department of Molecular Oncology.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Pre-screening:

Inclusion Criteria:

  • Has a -proven locally advanced or adenocarcinoma from colon or rectum
  • Has received or is receiving systemic treatment for mCRC
  • Has non-resectable metastases and eligible to undergo a radiological-guided core from at least one metastasis
  • (ECOG) performance status 0 or 1
  • Has measurable or evaluable disease (per v1.1)
  • Is capable of giving signed , as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria:

  • Has other medical conditions which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements.

MAIN STUDY:

Inclusion Criteria:

  1. Has a histologically-proven locally advanced or metastatic adenocarcinoma from colon or rectum (mCRC)
  2. Has received at least two lines of SOC chemotherapy for mCRC Note: 1) For patients who develop a metastatic relapse \< 6 months after completed total treatment in conjunction with a metastasectomy, this treatment will be considered as one line (e.g. ) chemotherapy. 2) Patients with the gene RAS wild-type tumors should have received or have been offered and refused prior treatment with antibodies against epidermal growth factor receptor (EGFR) (e.g. in combination with prior lines of chemotherapy) unless it was due to underlying conditions or the tumor contains molecular alterations suggested to provide primary resistance to EGFR-targeted therapy.
  3. Has full combined pharmacogenomic profile (genomic and transcriptomic profile of the patients tumor and ex vivo drug sensitivity testing of PDOs from the patient's own tumors cells) from which the MTB suggests a treatment with one of the defined targeted anti-cancer therapies provided this study
  4. Has measurable or evaluable disease (per RECIST v1.1)
  5. ECOG performance status 0 or 1
  6. For orally administered drugs, the participant must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
  7. Because of the risks of drug treatment to a developing fetus, women of and men must agree to use adequate in accordance with the respective SmPC and as listed in Appendix 4 for the duration of study participation, and up to 7 months following completion of study therapy. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or completely abstain from sexual intercourse.
  8. Has acceptable organ function as defined below. However, as noted below (exclusion criterion 16), drug-specific inclusion/exclusion criteria specified in the Appendix 16/respective SmPC for each agent will take precedence for this and all inclusion criteria:

    1. ≥ 1.5/nL (nL = nano Litre)
    2. > 10 g/dL
    3. > 100/nL
    4. Total \< 1.5 x institutional (ULN)
    5. AST (SGOT) and alanine aminotransferase ALT(SGPT) \< 2.5 x institutional upper limit of normal (ULN) (or \< 5 x ULN in patients with known hepatic metastases)
    6. Calculated or measured ≥ 50 mL/min/1.73 m2

Exclusion Criteria:

  1. Has ongoing toxicity > grade 2, other than peripheral neuropathy and alopecia, related to anti-tumor treatment that was completed within 4 weeks prior to registration. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.
  2. Has received previous treatment with the selected study drug for the same .
  3. Has a tumor with a genomic variant known to confer resistance to an anti-cancer agent available in this study, the patient will not be eligible to receive that agent but will be eligible to receive other drugs available in this study if all inclusion and exclusion criteria are met for that drug.
  4. Is receiving any other anti-cancer therapies (cytotoxic, biologic, radiation, or hormonal other than for replacement). Participants may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific exclusion criteria (please consult the corresponding SmPC and Appendix 16 for prohibited medication and contraindication/precautions).
  5. Is pregnant or breastfeeding or refusing any type of required contraception methods.
  6. Has known Central Nervous System (CNS) metastases.
  7. Has preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.
  8. Has (LVEF) known to be \< 40%.
  9. Has had a stroke (including ) or an acute myocardial infarction within 6 months before the first dose of study treatment.
  10. Has had acute gastrointestinal bleeding within 1 month of start of treatment
  11. Has other clinically significant medical conditions which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements.
  12. Meets any of the assigned drug contraindications or other drug-specific exclusion criteria as described in the respective SmPC and in Appendix 16
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Individualized treatment in patients with metastatic colorectal cancer

    Interventions with anti-cancer drugs having marketing authorisation in Norway will be used in this study. The intervention will be study drugs as monotherapy or treatment with approved combinations. This trial will facilitate access to potentially effective interventions to which they would otherwise not have access.

    Drug: Alectinib · Drug: Cetuximab · Drug: Crizotinib · Drug: Dasatinib · Drug: Everolimus · Drug: Encorafenib · Drug: Gemcitabine · Drug: Idelalisib · Drug: Larotrectinib · Drug: Methotrexate · Drug: Palbociclib · Drug: Panobinostat · Drug: Pembrolizumab · Drug: Petrozumab · Drug: Trastuzumab · Drug: Talazoparib · Drug: Venetoclax

Interventions

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • DrugPetrozumab

    Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

  • Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

06

What researchers measure

Primary outcomes

  1. Pre-Screening: Obtain a combined pharmacogenomic profile which can be used to provide a MTB-nominated treatment

    Number of participants that obtain a full combined pharmacogenomic profile which can be used to provide an MTB-nominated treatment in the Main Study.

    Time frame: In average of 3 months

  2. Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.

    Number of patients who achieve objective response according RECIST 1.1 in the total study population and each study drug cohort of MTB-nominated therapies with drugs not approved or implemented SOC for treatment of mCRC.

    Time frame: Through study completion, in average 6 months

Secondary outcomes

  1. Pre-Screening: To obtain a full combined pharmacogenomic profile from a tumor biopsy that is eligible for treatment decisions in a standard oncology practice.

    Pre-Screening: Number of participants who achieve a full combined pharmacogenomic profile eligible for treatment decisions either by * An MTB-nominated treatment provided in the Main Study * An MTB-nominated treatment considered as SOC * An MTB-nominated treatment not considered as SOC and not provided in the Main Study * No MTB-nominated treatment suggested

    Time frame: Through study completion, approximately 4 years

  2. Main Study: Progression-free survival (PFS) and duration of response (DOR)

    Progression-free survival (PFS) and duration of response (DOR) by RECIST 1.1, of participants receiving an MTB-nominated anti-cancer therapy, by calculation of number of days, weeks or years.

    Time frame: Through study completion, approximately 6 months

  3. Main Study: Overall survival (OS)

    OS of participants receiving MTB-nominated anti-cancer therapy, defined as the time from first dose of MTB-nominated treatment to date of death from any cause by calculation of number of days, weeks or years.

    Time frame: Through study completion, approximately 6 months

  4. Main Study: Safety and tolerability of the different MTB-nominated treatments

    Register adverse events (AE) in accordance with CTCAE v 5.1

    Time frame: Through study completion, approximately 6 months

  5. Main Study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the prior line(s) SOC treatment.

    Number of patients who achieve objective response according to RECIST 1.1 from anti-cancer therapy (SOC) in prior lines.

    Time frame: Through study completion, approximately 6 months

  6. Main Study: Efficacy of MTB-nominated anti-cancer therapy compared to the efficacy of prior lines SOC treatment.

    DOR and PFS by RECIST 1.1 of participants receiving an MTB-nominated treatment and from anti-cancer therapy received in prior lines of SOC in each patient, by calculation of number of days, weeks or years.

    Time frame: Through study completion, approximately 6 months.

  7. Main study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the next line(s) SOC treatment.

    Number of patients who achieve objective response according to RECIST 1.1 from receiving anti-cancer therapy in the next/later lines.

    Time frame: Through study completion, approximately 6 months.

  8. Main study: Efficacy of an MTB-nominated anti-cancer therapy compared to the efficacy achieved by the next line(s) of SOC treatment.

    DOR and PFS by RECIST 1.1 of participants receiving an MTB-nominated treatment and from anti-cancer therapy in the next/later lines of SOC treatment in each patient, by calculation of number of days, weeks or years.

    Time frame: Through study completion, approximately 6 months.

  9. Main study: Patient-reported outcome measures.

    Describe patient-reported quality of life during the MTB-nominated treatment, registered by EORTC Quality of Life Questionnaire (QLQ)-C30 questionnaire. The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.

    Time frame: Through study completion, approximately 6 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2038, 195 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 195 months is above that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Feb 13, 2023
StartActual
Sep 27, 2022
Primary completionEst.
Dec 31, 2038
CompletionEst.
Dec 31, 2040
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05725200
Responsible party
Tormod Kyrre Guren, MD (Principal Investigator, Oslo University Hospital) — Principal investigator
First posted
Feb 13, 2023
Start date
Sep 27, 2022
Primary completion
Dec 31, 2038 (estimated)
Completion
Dec 31, 2040 (estimated)
Last update
Feb 21, 2023

Study contacts

Tormod K Guren, MDPhD
Contact
uxtour@ous-hf.no
+4722934000
Tormod K Guren, MDPhD
principal investigator · Oslo University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alectinib · Cetuximab · Crizotinib · Dasatinib · Everolimus · Encorafenib · Gemcitabine · Idelalisib · Larotrectinib · Methotrexate · Palbociclib · Panobinostat · Trastuzumab · Talazoparib · Venetoclax

Start the discussion